國家衛生研究院 NHRI:Item 3990099045/7514

NHRI > National Institute of Infectious Diseases and Vaccinology > Hsin-Wei Chen > Periodical Articles > Item 3990099045/7514

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7514

Title:	Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement
Authors:	Chiang, CY;Pan, CH;Hsieh, CH;Tsai, JP;Chen, MY;Liu, HH;Liu, SJ;Chong, P;Leng, CH;Chen, HW
Contributors:	Division of Vaccine Research and Development
Abstract:	BACKGROUND: Dengue virus is a mosquito-transmitted virus that can cause self-limiting dengue fever, severe life-threatening dengue hemorrhagic fever and dengue shock syndrome. The existence of four serotypes of dengue virus has complicated the development of an effective and safe dengue vaccine. Recently, a clinical phase 2b trial of Sanofi Pasteur's CYD tetravalent dengue vaccine revealed that the vaccine did not confer full protection against dengue-2 virus. New approaches to dengue vaccine development are urgently needed. Our approach represents a promising method of dengue vaccine development and may even complement the deficiencies of the CYD tetravalent dengue vaccine. METHODOLOGY/PRINCIPAL FINDINGS: Two important components of a vaccine, the immunogen and immunopotentiator, were combined into a single construct to generate a new generation of vaccines. We selected dengue-2 envelope protein domain III (D2ED III) as the immunogen and expressed this protein in lipidated form in Escherichia coli, yielding an immunogen with intrinsic immunopotentiation activity. The formulation containing lipidated D2ED III (LD2ED III) in the absence of exogenous adjuvant elicited higher D2ED III-specific antibody responses than those obtained from its nonlipidated counterpart, D2ED III, and dengue-2 virus. In addition, the avidity and neutralizing capacity of the antibodies induced by LD2ED III were higher than those elicited by D2ED III and dengue-2 virus. Importantly, we showed that after lipidation, the subunit candidate LD2ED III exhibited increased immunogenicity while reducing the potential risk of antibody-dependent enhancement of infection in mice. CONCLUSIONS/SIGNIFICANCE: Our study suggests that the lipidated subunit vaccine approach could be applied to other serotypes of dengue virus and other pathogens.
Date:	2013-09-19
Relation:	PLoS Neglected Tropical Diseases. 2013 Sep 19;7(9):Article number e2432.
Link to:	http://dx.doi.org/10.1371/journal.pntd.0002432
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1935-2735&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000324920800037
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84884697281
Appears in Collections:	[Hsin-Wei Chen] Periodical Articles [Chih-Hsiang Leng] Periodical Articles [Shih-Jen Liu] Periodical Articles [Chien-Hsiung Pan] Periodical Articles [Pele Choi-Sing Chong] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB24069487.pdf		566Kb	Adobe PDF	668	View/Open

Loading...